{"id":521844,"date":"2021-08-03T06:33:56","date_gmt":"2021-08-03T10:33:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/zimmer-biomet-announces-second-quarter-2021-financial-results\/"},"modified":"2021-08-03T06:33:56","modified_gmt":"2021-08-03T10:33:56","slug":"zimmer-biomet-announces-second-quarter-2021-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/zimmer-biomet-announces-second-quarter-2021-financial-results\/","title":{"rendered":"Zimmer Biomet Announces Second Quarter 2021 Financial Results"},"content":{"rendered":"
\n

– Second quarter net sales of $2.027 billion increased 65.3%, 60.7% on a constant currency(1) basis<\/h2>\n

– Second quarter diluted earnings per share were $0.67; adjusted(1) diluted earnings per share were $1.90<\/h2>\n

– Company updates 2021 financial guidance, narrowing range for full year outlook<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n WARSAW, Ind.<\/span>, Aug. 3, 2021<\/span> \/PRNewswire\/ —\u00a0Zimmer Biomet Holdings, Inc. (NYSE and SIX:\u00a0ZBH) today reported financial results for the quarter ended June\u00a030, 2021.\u00a0 The Company reported second\u00a0quarter net sales of $2<\/span>.027\u00a0billion, an increase of 65.3% over the prior year period, and an increase of 60.7% on a constant currency basis.\u00a0 Second quarter 2021 net sales increased 1.9% when compared to the pre-pandemic second quarter 2019, and were flat on a constant currency basis. Net earnings for the second quarter of 2021 were $141.9 million<\/span>, or $400.5 million<\/span> on an adjusted basis.<\/p>\n

\n

\n
\n \"\"
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Diluted earnings per share were $0.67<\/span> for the second quarter.\u00a0 Adjusted diluted earnings per share were $1.90<\/span> for the second quarter.\u00a0<\/p>\n

“Our performance in the second quarter improved meaningfully from the first quarter 2021 across all regions and product categories as recovery from the global pandemic continued to take hold. While we anticipate some ongoing COVID-19 pressure, we expect continued improvement in procedure volume recovery through the second half of 2021,” said Bryan Hanson<\/span>, Chairman, President and CEO of Zimmer Biomet. “Against this backdrop, Zimmer Biomet has continued to execute, investing in our business, expanding our portfolio and developing and launching innovative products designed to improve mobility and health. This execution enables ZB to build and deliver value for our customers and shareholders and to move our mission forward for the patients we ultimately serve.”<\/p>\n

Please see the attached schedules accompanying this press release for additional details on performance in the quarter, including sales by Zimmer Biomet’s three geographies and five product categories.<\/p>\n

_________________________
1<\/sup> Reconciliations of these measures to the corresponding U.S. generally accepted accounting principles measures are included in this press release.<\/p>\n

\n Recent Highlights<\/b>\n <\/p>\n

Aligned with the ongoing transformation of Zimmer Biomet’s business, key recent highlights include:<\/p>\n